Emerging Strategies in the Upfront Treatment of Hodgkin Lymphoma

Join Robert Chen, MD from City of Hope Comprehensive Cancer Center for this NCCN webinar presentation, Emerging Strategies in the Upfront Treatment of Hodgkin Lymphoma.

Target Audience

This initiative is designed to meet the needs of oncologists, hematologists, nurses, pharmacists, physician assistants, and other health care professionals treating Hodgkin lymphoma (HL) patients.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the need for improved treatment options for newly diagnosed Hodgkin lymphoma (HL) patients.
  • Discuss the upfront use of antibody-drug conjugates combined with standard chemotherapy.
  • Comment on the upfront use of PD-1 immune checkpoint inhibitors.
Additional information
Supporters: 

This activity is supported by an educational grant from Seattle Genetics, Inc.

Course summary
Available credit: 
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.72 ANCC contact hours
  • 0.75 Participation
Course opens: 
03/08/2018
Course expires: 
03/08/2019
Cost:
$0.00

Robert Chen, MD
City of Hope Comprehensive Cancer Center

 

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Definitions:
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
 
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Faculty Disclaimers:
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures:
The faculty listed below discloses the following relevant financial relationships:
Robert Chen, MD
Bristol-Myers Squibb Company: Scientific Advisor
Merck & Co., Inc.: Product/Speakers Bureau; Scientific Advisor
Seattle Genetics, Inc.: Product/Speakers Bureau; Scientific Advisor

NCCN Staff Disclosures:
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Heather Matt; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio, MS; Liz Rieder; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Melinda Somasekhar, PhD (employed by NCCN until 10/30/2017)

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Ndiya Ogba, PhD

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.75 hours of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 0.72 contact hours.

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 0.75 contact hours (0.075 CEUs) of continuing education credit. UAN = 0836-0000-18-056-H01-P

Available Credit

  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.72 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing